Data / Form D filings / Invea Therapeutics, Inc
Invea Therapeutics, Inc: Form D filings
Invea Therapeutics, Inc, a biotechnology company in Guilford, CT, filed 3 Form D notices with the SEC between 2022 and 2025. The latest, on December 10, 2025, reports $120,250 sold of a $120,250 offering to 1 investor.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2614 BOSTON POST ROAD, SUITE 33B, Guilford, CT, 06437
- Phone
- (203) 643-8002
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2021
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1906425
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Dec 10, 2025 | New notice | $120,250 | $120,250 | 1 | Oct 31, 2025 | sec.gov | |
| Apr 9, 2025 | New notice | $600,000 | $300,000 | $300,000 | 2 | Mar 31, 2025 | sec.gov |
| Apr 22, 2022 | New notice | $5,760,000 | $1,524,994 | $4,235,006 | 4 | Apr 7, 2022 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Demetrios J. Kydonieus | Director | |
| Aman Kant | Executive Officer | |
| Salvatore J. Alesci | Executive Officer | |
| Michael J. Aiello | Executive Officer | |
| Jonathan J. Zalevsky | Director | |
| "Shunichiro ""Steve""" J. Okada | Executive Officer | |
| Stephen J. Doberstein | Director | |
| Kerrie J. Brady | Director | |
| Krishnan Nandabalan | Executive Officer, Director |
Other biotechnology companies in Connecticut that filed recently
- Allyx Therapeutics, Inc. $27.9 million · Oct 21, 2026
- Cloverleaf Bio, Inc. $14.8 million · Sep 9, 2026
Every Form D from the week of Dec 8, 2025 · All recent filings in Connecticut · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Invea Therapeutics, Inc reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.